Vimpat

Vimpat

lacosamide

Manufacturer:

UCB

Distributor:

Zuellig
/
Agencia Lei Va Hong
Concise Prescribing Info
Contents
Lacosamide
Indications/Uses
Monotherapy & adjunctive therapy in the treatment of partial-onset seizures w/ or w/o secondary generalisation in adults, adolescents & childn ≥4 yr w/ epilepsy.
Dosage/Direction for Use
Adult, adolescent & childn ≥50 kg Monotherapy 50 mg bd. Increase to initial therapeutic dose of 100 mg bd after 1 wk. Can also be initiated at 100 mg bd. Maintenance dose: Can be further increased at wkly intervals by 50 mg bd. Max: 300 mg bd. Adjunctive therapy 50 mg bd. Increase to 100 mg bd after 1 wk. Maintenance dose: Can be further increased at wkly intervals by 50 mg bd. Max: 200 mg bd. Loading dose Treatment may also be initiated w/ 200 mg single loading dose, followed approx 12 hr later by 100 mg bd (200 mg/day) maintenance dose. Mild or moderate renal impairment No dose adjustment necessary. 200 mg loading dose may be considered, but perform further dose titration (>200 mg daily) w/ caution. Severe renal impairment or end-stage renal disease Max: 250 mg/day. Perform dose titration w/ caution. Mild to moderate hepatic impairment Max: 300 mg/day. Childn ≥4 yr & adolescent <50 kg Dose is determined based on body wt. Monotherapy 2 mg/kg/day. Increase to initial therapeutic dose of 4 mg/kg/day after 1 wk. Maintenance dose: Can be further increased by 2 mg/kg/day every wk. Max in childn 40 to <50 kg: 10 mg/kg/day. Max dose in childn <40 kg: 12 mg/kg/day. Adjunctive therapy 2 mg/kg/day. Increase to initial therapeutic dose of 4 mg/kg/day after 1 wk. Maintenance dose: Can be further increased by 2 mg/kg/day every wk. Max in childn 30 to <50 kg: 8 mg/kg/day. Max in childn 20 to <30 kg: 10 mg/kg/day. Max dose in childn <20 kg: 12 mg/kg/day.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. 2nd or 3rd degree AV block.
Special Precautions
Monitor for signs of suicidal ideation & behaviours. Dose-related PR interval prolongation. Use w/ caution in patients w/ underlying proarrhythmic conditions (eg, cardiac conduction problems or severe cardiac disease or patients on medicines affecting cardiac conduction) & elderly. Monitor for symptoms of 2nd-degree or higher AV block. Associated w/ dizziness. Patients on a controlled Na diet (for syr & soln for infusion). May impair ability to drive or operate machinery. Pregnancy & lactation. Paed patients w/ epilepsy syndromes in which focal & generalised seizures may coexist. Syr: Contains Na methyl parahydroxybenzoate which may cause allergic reactions. Patients w/ rare hereditary problems of fructose intolerance. Patients w/ phenylketonuria.
Adverse Reactions
Dizziness, headache, nausea, diplopia. Depression, confusional state, insomnia, vision blurred, vertigo, dyspepsia, diarrhea. Dose-related increase in PR interval. Paed population: Nasopharyngitis, vomiting, somnolence, dizziness, pyrexia, convulsion. Decreased appetite, lethargy, abnormal behaviour.
Drug Interactions
Use w/ caution if concomitantly administered w/ drugs known to be associated w/ PR prolongation (eg, Na channel-blocking antiepileptic drugs) & antiarrhythmics.
MIMS Class
Anticonvulsants
ATC Classification
N03AX18 - lacosamide ; Belongs to the class of other antiepileptics.
Presentation/Packing
Form
Vimpat FC tab 50 mg
Packing/Price
56's
Form
Vimpat FC tab 100 mg
Packing/Price
56's
Form
Vimpat syr 10 mg/mL
Packing/Price
1's
Form
Vimpat soln for infusion 10 mg/mL
Packing/Price
20 mL x 5 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in